A detailed history of Cambridge Advisors Inc. transactions in Pfizer Inc stock. As of the latest transaction made, Cambridge Advisors Inc. holds 9,493 shares of PFE stock, worth $250,235. This represents 0.06% of its overall portfolio holdings.

Number of Shares
9,493
Previous 9,368 1.33%
Holding current value
$250,235
Previous $262,000 4.58%
% of portfolio
0.06%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$27.7 - $31.39 $3,462 - $3,923
125 Added 1.33%
9,493 $274,000
Q2 2024

Jul 11, 2024

BUY
$25.26 - $29.6 $34,732 - $40,700
1,375 Added 17.2%
9,368 $262,000
Q1 2024

Apr 16, 2024

SELL
$25.89 - $29.73 $3,883 - $4,459
-150 Reduced 1.84%
7,993 $221,000
Q4 2023

Jan 16, 2024

SELL
$26.13 - $33.94 $28,533 - $37,062
-1,092 Reduced 11.82%
8,143 $234,000
Q3 2023

Oct 18, 2023

SELL
$32.09 - $37.51 $17,809 - $20,818
-555 Reduced 5.67%
9,235 $306,000
Q2 2023

Jul 13, 2023

SELL
$36.12 - $41.79 $67,616 - $78,230
-1,872 Reduced 16.05%
9,790 $359,000
Q1 2023

Apr 13, 2023

SELL
$39.39 - $51.28 $3,229 - $4,204
-82 Reduced 0.7%
11,662 $475,000
Q4 2022

Jan 23, 2023

SELL
$41.75 - $54.5 $10,270 - $13,407
-246 Reduced 2.05%
11,744 $0
Q3 2022

Oct 17, 2022

BUY
$43.76 - $53.42 $700 - $854
16 Added 0.13%
11,990 $525,000
Q2 2022

Jul 18, 2022

SELL
$46.53 - $55.17 $4,001 - $4,744
-86 Reduced 0.71%
11,974 $628,000
Q1 2022

May 05, 2022

SELL
$45.75 - $56.69 $6,405 - $7,936
-140 Reduced 1.15%
12,060 $624,000
Q4 2021

Jan 14, 2022

BUY
$41.32 - $61.25 $27,808 - $41,221
673 Added 5.84%
12,200 $720,000
Q3 2021

Oct 19, 2021

SELL
$39.25 - $50.42 $4,435 - $5,697
-113 Reduced 0.97%
11,527 $496,000
Q2 2021

Jul 21, 2021

SELL
$35.91 - $40.68 $8,582 - $9,722
-239 Reduced 2.01%
11,640 $456,000
Q1 2021

Apr 22, 2021

BUY
$33.49 - $37.77 $33 - $37
1 Added 0.01%
11,879 $430,000
Q4 2020

Jan 25, 2021

BUY
$33.47 - $42.56 $4,016 - $5,107
120 Added 1.02%
11,878 $437,000
Q3 2020

Oct 15, 2020

BUY
$31.75 - $37.25 $95 - $111
3 Added 0.03%
11,758 $432,000
Q2 2020

Jul 17, 2020

SELL
$30.12 - $36.54 $21,475 - $26,053
-713 Reduced 5.72%
11,755 $384,000
Q1 2020

Apr 21, 2020

BUY
$27.03 - $38.62 $22,570 - $32,247
835 Added 7.18%
12,468 $407,000
Q4 2019

Jan 28, 2020

BUY
$32.92 - $37.36 $592 - $672
18 Added 0.15%
11,633 $456,000
Q3 2019

Oct 25, 2019

SELL
$32.49 - $42.13 $4,581 - $5,940
-141 Reduced 1.2%
11,615 $417,000
Q2 2019

Jul 26, 2019

SELL
$36.98 - $41.52 $144,000 - $161,678
-3,894 Reduced 24.88%
11,756 $509,000
Q1 2019

Apr 16, 2019

BUY
$37.5 - $41.2 $600 - $659
16 Added 0.1%
15,650 $665,000
Q4 2018

Jan 29, 2019

BUY
$38.47 - $43.86 $64,321 - $73,333
1,672 Added 11.98%
15,634 $682,000
Q3 2018

Oct 24, 2018

SELL
$34.47 - $41.81 $113,337 - $137,471
-3,288 Reduced 19.06%
13,962 $615,000
Q2 2018

Jul 30, 2018

BUY
$32.98 - $35.16 $1,055 - $1,125
32 Added 0.19%
17,250 $626,000
Q1 2018

Apr 18, 2018

BUY
$31.91 - $37.02 $21,475 - $24,914
673 Added 4.07%
17,218 $611,000
Q4 2017

Jan 26, 2018

BUY
$33.26 - $35.29 $54,546 - $57,875
1,640 Added 11.0%
16,545 $599,000
Q3 2017

Oct 27, 2017

BUY
$31.0 - $34.15 $462,055 - $509,005
14,905
14,905 $532,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $148B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Cambridge Advisors Inc. Portfolio

Follow Cambridge Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Advisors Inc. with notifications on news.